Menlo Therapeutics Inc (MNLO):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Menlo Therapeutics Inc (MNLO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8270)・商品コード:DATA904C8270
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:36
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Menlo Therapeutics Inc (Menlo Therapeutics) formerly Tigercat Pharma Inc, is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions such as psoriasis and prurigo nodularis, and for refractory chronic cough. Its pipeline product candidate serlopitant, is a small molecule, highly selective NK1-R antagonist which reduces pruritus and refractory chronic cough symptoms. The company has licensing opportunities for development and commercialization of its pipeline product in all markets other than Japan. Menlo Therapeutics is headquartered in Redwood City, California, the US.

Menlo Therapeutics Inc (MNLO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Menlo Therapeutics Raises USD50 Million in Series C Financing 10
Tigercat Pharma Raises Funds Through Venture Financing 12
Tigercat Pharma Raises US$0.5 Million In Venture Financing 13
Menlo Therapeutics Raises USD14.5 Million in Series A Financing 14
Licensing Agreements 15
Menlo Therapeutics Enters into Licensing Agreement with Merck 15
Equity Offering 16
Menlo Therapeutics Raises USD137 Million in IPO 16
Menlo Therapeutics Raises USD45 Million in Private Placement of Preferred Stock 18
Menlo Therapeutics Inc – Key Competitors 19
Menlo Therapeutics Inc – Key Employees 20
Menlo Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
May 09, 2018: Menlo Therapeutics Reports First Quarter 2018 Financial Results 22
Mar 28, 2018: Menlo Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 24
Corporate Communications 26
Jan 05, 2017: Menlo Therapeutics announces management changes 26
Product News 27
10/17/2017: Menlo Therapeutics Expands its Management Team 27
01/05/2017: Menlo Therapeutics Recruits Experienced Management Team and Board Leadership to Accelerate Development of Serlopitant for Treatment of Pruritus 28
Clinical Trials 29
Apr 08, 2018: Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis 29
Feb 20, 2018: Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of Dermatology 30
Nov 21, 2017: Menlo Therapeutics Begins Phase 2 Clinical Trial for Pruritus Associated with Psoriasis 31
Oct 26, 2017: Menlo Therapeutics Initiates Enrollment in Phase 2 Clinical Trial with Serlopitant for Refractory Chronic Cough 32
Sep 18, 2017: Serlopitant Pruritus Reduction Results from Two Phase 2 Studies Presented at the 26th European Academy of Dermatology and Venereology 33
Mar 08, 2017: Menlo Therapeutics Announces Successful Pruritus Reduction Results from Phase 2 Serlopitant Trial (TCP-102) in 127 Subjects With Prurigo Nodularis 34
Jan 06, 2017: Menlo Therapeutics Starts Enrollment in Two Phase 2 Studies for Pruritus Associated with Atopic Dermatitis and Pruritus Following Burn Injury 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Menlo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Menlo Therapeutics Raises USD50 Million in Series C Financing 10
Tigercat Pharma Raises Funds Through Venture Financing 12
Tigercat Pharma Raises US$0.5 Million In Venture Financing 13
Menlo Therapeutics Raises USD14.5 Million in Series A Financing 14
Menlo Therapeutics Enters into Licensing Agreement with Merck 15
Menlo Therapeutics Raises USD137 Million in IPO 16
Menlo Therapeutics Raises USD45 Million in Private Placement of Preferred Stock 18
Menlo Therapeutics Inc, Key Competitors 19
Menlo Therapeutics Inc, Key Employees 20

List of Figures
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Menlo Therapeutics Inc (MNLO):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8270)販売に関する免責事項を必ずご確認ください。
★調査レポート[Menlo Therapeutics Inc (MNLO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆